Jörge E. Cortes
Impact in
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 1.8k
- Chronic Myeloid Leukemia Treatments 1.3k
- Acute Myeloid Leukemia Research 778
- Multiple Myeloma Research and Treatments 100
- Genetics 1.2k
- Chronic Lymphocytic Leukemia Research 925
- Myeloproliferative Neoplasms: Diagnosis and Treatment 288
- Co-authors
- Hagop M. Kantarjian (251 shared papers)Susan O’Brien (251 shared papers)Francis J. Giles (251 shared papers)Guillermo Garcia‐Manero (251 shared papers)Farhad Ravandi (251 shared papers)Deborah A. Thomas (251 shared papers)Stefan Faderl (251 shared papers)Elias Jabbour (251 shared papers)
- Journals
- Blood (906 papers)Journal of Clinical Oncology (300 papers)Cancer (204 papers)American Journal of Hematology (59 papers)Leukemia (49 papers)
- Partner nations
- United StatesGermanyItaly
In The Last Decade
Jörge E. Cortes
2.2k papers receiving 84.0k citations
Jörge E. Cortes's Hit Papers
Peers
Comparison fields: 5 of 177
- Hematology 57.6k
- Genetics 34.8k
- Rheumatology 16.0k
- Oncology 13.0k
- Pathology and Forensic Medicine 7.7k
Countries citing papers authored by Jörge E. Cortes
This map shows the geographic impact of Jörge E. Cortes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörge E. Cortes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörge E. Cortes more than expected).
Fields of papers citing papers by Jörge E. Cortes
This network shows the impact of papers produced by Jörge E. Cortes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörge E. Cortes. The network helps show where Jörge E. Cortes may publish in the future.
Co-authors
The 25 scholars most cited alongside Jörge E. Cortes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 2.3k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2006 | 1291 |
| 2 | Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Hit paper breakdown → | 2010 | 1108 |
| 3 | Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL Hit paper breakdown → | 2006 | 974 |
| 4 | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet Hit paper breakdown → | 2009 | 892 |
| 5 | Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis Hit paper breakdown → | 2010 | 856 |
| 6 | Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia Hit paper breakdown → | 2005 | 705 |
| 7 | Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Hit paper breakdown → | 2003 | 632 |
| 8 | Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial Hit paper breakdown → | 2016 | 631 |
| 9 | Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia Hit paper breakdown → | 2000 | 592 |
| 10 | Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity Hit paper breakdown → | 2010 | 590 |
| 11 | Acute myeloid leukaemia Hit paper breakdown → | 2018 | 562 |
| 12 | Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents Hit paper breakdown → | 2013 | 546 |
| 13 | Molecular biology of bcr-abl1–positive chronic myeloid leukemia Hit paper breakdown → | 2008 | 532 |
| 14 | Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2012 | 531 |
| 15 | Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Hit paper breakdown → | 2006 | 517 |
| 16 | Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Hit paper breakdown → | 2008 | 509 |
| 17 | 2006 | 470 | |
| 18 | 2001 | 468 | |
| 19 | 2004 | 461 | |
| 20 | Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) Hit paper breakdown → | 2011 | 444 |
About Jörge E. Cortes
Jörge E. Cortes is a scholar working on Hematology, Genetics, Rheumatology, Public Health, Environmental and Occupational Health and Molecular Biology, having authored 2.3k papers that have together received 85.8k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (1.3k papers), Chronic Lymphocytic Leukemia Research (925 papers), Acute Myeloid Leukemia Research (778 papers), Eosinophilic Disorders and Syndromes (417 papers), Acute Lymphoblastic Leukemia research (373 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (288 papers), Lymphoma Diagnosis and Treatment (108 papers) and Multiple Myeloma Research and Treatments (100 papers). The work is most often cited by research in Hematology (57.6k citations), Genetics (34.8k citations), Rheumatology (16.0k citations), Oncology (13.0k citations) and Pathology and Forensic Medicine (7.7k citations). Jörge E. Cortes has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Hagop M. Kantarjian, Susan O’Brien, Francis J. Giles, Guillermo Garcia‐Manero, Farhad Ravandi, Deborah A. Thomas, Stefan Faderl, Elias Jabbour, Srđan Verstovšek and Alfonso Quintás‐Cardama. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, American Journal of Hematology and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.